Clinical Trials Logo

Refractory T-Cell Lymphoma clinical trials

View clinical trials related to Refractory T-Cell Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06151106 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

NCT ID: NCT04470947 Recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

EXALT-2
Start date: June 10, 2020
Phase:
Study type: Observational [Patient Registry]

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

NCT ID: NCT04251065 Active, not recruiting - Clinical trials for Relapsed T-Cell Lymphoma

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Start date: September 3, 2020
Phase: Phase 2
Study type: Interventional

FIL_Dara-GDP is a phase II, open label, multicenter clinical trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL). The primary objective is to evaluate the efficacy of 4 courses of D-GDP (Daratumumab in combination with Gemcitabine, Cisplatin, Dexamethasone) in terms of complete response in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of T follicular helper cells (TFH cells) origin refractory/relapsed after at least one and no more than two previous lines of therapy.

NCT ID: NCT04217317 Recruiting - Clinical trials for Non Hodgkin Lymphoma

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Start date: September 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.

NCT ID: NCT04162340 Recruiting - Clinical trials for Refractory T-Cell Lymphoma

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Start date: July 11, 2019
Phase: Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD4 CAR T cells in patients with relapsed and/or refractory T cell lymphoma.

NCT ID: NCT01878708 Terminated - T-Cell Lymphoma Clinical Trials

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

Start date: July 2013
Phase: Early Phase 1
Study type: Interventional

This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.